Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Verteporfin Blocks Growth of Deadly Eye Melanoma

By BiotechDaily International staff writers
Posted on 08 Jun 2014
Image: An untreated uveal melanoma tumor (left) covers entire eye of a mouse. A tumor treated with verteporfin (right) is much smaller and much of the structure of the mouse\'s eye is visible (Photo courtesy of UCSD - University of California, San Diego).
Image: An untreated uveal melanoma tumor (left) covers entire eye of a mouse. A tumor treated with verteporfin (right) is much smaller and much of the structure of the mouse\'s eye is visible (Photo courtesy of UCSD - University of California, San Diego).
Simultaneous mutations in two G-protein encoding genes that cause the overexpression of a carcinogenic protein have been linked to the development of uveal melanoma, a deadly cancer of the colored areas of the eye.

Uveal melanoma is a rare cancer that is usually treated by surgical removal of the eye. However, uveal melanoma can spread to the liver, in which case patients typically die within two to eight months after diagnosis.

Genome studies have shown that a mutation in either the GNAQ (guanine nucleotide binding protein, q polypeptide) or GNA11 (guanine nucleotide-binding protein subunit alpha-11) genes, which encode the proteins Gq or G11, respectively, are found in about 70% of uveal melanoma tumors.

In the current study, which was published in the May 29, 2014, online edition of the journal Cancer Cell, investigators at the University of California, San Diego (USA) revealed that that these mutations cause the G-proteins to become permanently activated, which results in overexpression of the Yes-associated protein (YAP). Overexpression of YAP protein induces uncontrolled cell growth and inhibits cell death, triggering cancer development. Furthermore, treatment of uveal melanoma tumors with the YAP inhibitor drug verteporfin blocked tumor growth of cells containing Gq/G11 mutations.

“The beauty of our study is its simplicity,” said senior author Dr. Kun-Liang Guan, professor of pharmacology at the University of California, San Diego. “The genetics of this cancer are very simple and our results have clear implications for therapeutic treatments for the disease. We have a cancer that is caused by a very simple genetic mechanism, and we have a drug that works on this mechanism. The clinical applications are very direct.”

Related Links:

University of California, San Diego



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.